ACAD Quote, Financials, Valuation and Earnings

Oragenics has a net margin of 55.37% compared to ACADIA Pharmaceuticals's net margin of --. ACADIA Pharmaceuticals's return on equity of 41.59% beat Oragenics's return on equity of --.

ACADIA Pharmaceuticals has a consensus price target of $24.68, signalling upside risk potential of 67.58%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 407.61%. Given that Oragenics has higher upside potential than ACADIA Pharmaceuticals, analysts believe Oragenics is more attractive than ACADIA Pharmaceuticals.

ACADIA Pharmaceuticals has a beta of 0.537, which suggesting that the stock is 46.313% less volatile than S&P 500. In comparison Oragenics has a beta of 0.868, suggesting its less volatile than the S&P 500 by 13.16%.

ACADIA Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

ACADIA Pharmaceuticals quarterly revenues are $259.6M, which are larger than Oragenics quarterly revenues of --. ACADIA Pharmaceuticals's net income of $143.7M is higher than Oragenics's net income of -$3.3M. Notably, ACADIA Pharmaceuticals's price-to-earnings ratio is 10.83x while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals is 2.56x versus 1.23x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of 55.37% compared to ACADIA Pharmaceuticals's net margin of --. ACADIA Pharmaceuticals's return on equity of 41.59% beat Palatin Technologies's return on equity of --.

ACADIA Pharmaceuticals has a consensus price target of $24.68, signalling upside risk potential of 67.58%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 3281.64%. Given that Palatin Technologies has higher upside potential than ACADIA Pharmaceuticals, analysts believe Palatin Technologies is more attractive than ACADIA Pharmaceuticals.

ACADIA Pharmaceuticals has a beta of 0.537, which suggesting that the stock is 46.313% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

ACADIA Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

ACADIA Pharmaceuticals quarterly revenues are $259.6M, which are larger than Palatin Technologies quarterly revenues of --. ACADIA Pharmaceuticals's net income of $143.7M is higher than Palatin Technologies's net income of --. Notably, ACADIA Pharmaceuticals's price-to-earnings ratio is 10.83x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals is 2.56x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

SpringWorks Therapeutics has a net margin of 55.37% compared to ACADIA Pharmaceuticals's net margin of -125.59%. ACADIA Pharmaceuticals's return on equity of 41.59% beat SpringWorks Therapeutics's return on equity of -46.69%.

ACADIA Pharmaceuticals has a consensus price target of $24.68, signalling upside risk potential of 67.58%. On the other hand SpringWorks Therapeutics has an analysts' consensus of $70.86 which suggests that it could grow by 58.45%. Given that ACADIA Pharmaceuticals has higher upside potential than SpringWorks Therapeutics, analysts believe ACADIA Pharmaceuticals is more attractive than SpringWorks Therapeutics.

ACADIA Pharmaceuticals has a beta of 0.537, which suggesting that the stock is 46.313% less volatile than S&P 500. In comparison SpringWorks Therapeutics has a beta of 0.787, suggesting its less volatile than the S&P 500 by 21.261%.

ACADIA Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SpringWorks Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals pays -- of its earnings as a dividend. SpringWorks Therapeutics pays out -- of its earnings as a dividend.

ACADIA Pharmaceuticals quarterly revenues are $259.6M, which are larger than SpringWorks Therapeutics quarterly revenues of $61.5M. ACADIA Pharmaceuticals's net income of $143.7M is higher than SpringWorks Therapeutics's net income of -$77.3M. Notably, ACADIA Pharmaceuticals's price-to-earnings ratio is 10.83x while SpringWorks Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals is 2.56x versus 17.30x for SpringWorks Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of 55.37% compared to ACADIA Pharmaceuticals's net margin of --. ACADIA Pharmaceuticals's return on equity of 41.59% beat Theriva Biologics's return on equity of --.

ACADIA Pharmaceuticals has a consensus price target of $24.68, signalling upside risk potential of 67.58%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 322.27%. Given that Theriva Biologics has higher upside potential than ACADIA Pharmaceuticals, analysts believe Theriva Biologics is more attractive than ACADIA Pharmaceuticals.

ACADIA Pharmaceuticals has a beta of 0.537, which suggesting that the stock is 46.313% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.169, suggesting its more volatile than the S&P 500 by 16.92%.

ACADIA Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

ACADIA Pharmaceuticals quarterly revenues are $259.6M, which are larger than Theriva Biologics quarterly revenues of --. ACADIA Pharmaceuticals's net income of $143.7M is higher than Theriva Biologics's net income of -$4.4M. Notably, ACADIA Pharmaceuticals's price-to-earnings ratio is 10.83x while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals is 2.56x versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.